StreetInsider.com News Articles

Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Thu, 10 Sep 2026 07:00:00 -0400

LOS ANGELES, Sept. 10, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Deborah Birx, M.D., Chief Executive Officer, will participate in a corporate presentation at the H.C. Wainwright 28th Annual Global Investment Conference, which is being held in New York from September 14-16, 2026.

Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Thu, 10 Sep 2026 07:00:00 -0400

Armata Pharmaceuticals publishes phage biology study in molecular journal

Thu, 03 Sep 2026 07:01:02 -0400

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) announced the publication of a peer-reviewed paper in the Journal of Molecular Biology examining the structural biology of a bacteriophage used in its clinical pipeline.

The paper, titled "Insights into Genome Ejection by a Therapeutic phiKMV-like Bacteriophage," presents a structural analysis of Ar-KM, a phage that targets Pseudomonas aeruginosa. Ar-KM is a component of Armata's AP-PA02 program, an inhaled bacteriophage candidate that has completed Phase 2 clinical studies in cystic fibrosis and non-CF bronchiectasis patients with chronic pulmonary P. aeruginosa infection.

Using cryo-electron microscopy, proteomics, and bioinformatics, researchers captured three distinct states of the phage particle

Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials

Thu, 03 Sep 2026 07:00:00 -0400

LOS ANGELES, Sept. 3, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced a paper in the Journal of Molecular Biology, a peer-reviewed journal.

Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials

Thu, 03 Sep 2026 07:00:00 -0400

Armata Pharmaceuticals, Inc. (ARMP) Tops Q2 EPS by 17c

Wed, 12 Aug 2026 16:47:22 -0400

Armata Pharmaceuticals, Inc. (NYSE: ARMP) reported Q2 EPS of ($0.27), $0.17 better than the analyst estimate of ($0.44). Revenue for the quarter came in at $2.51 million versus the consensus estimate of $420 thousand.

For earnings history and earnings-related data on Armata Pharmaceuticals, Inc. (ARMP) click here.

Form 10-Q Armata Pharmaceuticals, For: Jun 30

Wed, 12 Aug 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260812/26913299.html

Form 10-Q Armata Pharmaceuticals, For: Jun 30

Wed, 12 Aug 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260812/26913299.html

Form 8-K Armata Pharmaceuticals, For: Aug 12

Wed, 12 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260812/26913141.html

Form 8-K Armata Pharmaceuticals, For: Aug 12

Wed, 12 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260812/26913141.html

Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update